Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mette S. van Ramshorst"'
Autor:
Marte C. Liefaard, Mette S. van Ramshorst, Marie-Jeanne T. F. D. Vrancken Peeters, Anna van der Voort, Linda de Munck, Jelle Wesseling, Erik van Werkhoven, Gabe S. Sonke, A.N. Scholten
Publikováno v:
Cancer Research. 81:PS10-07
Background Pertuzumab greatly improves pathologic complete response (pCR) rates in early stage HER2-positive breast cancer. Long-term benefit of pertuzumab, however, is less well established, as follow-up of the NEOSPHERE and APHINITY trials did not
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Emma J. Groen, Mette S. van Ramshorst, Frederieke van Duijnhoven, Ritse M. Mann, Esther H. Lips, Jelle Wesseling, Gabe S. Sonke, Michael Schaapveld, Marieke E. M. van der Noordaa
Publikováno v:
Breast Cancer Research and Treatment, 189, 213-224
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Purpose The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive componen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf29fcec7f5f5dd928682cd323e1e44
http://hdl.handle.net/2066/238668
http://hdl.handle.net/2066/238668
Autor:
Gabe S. Sonke, Maartje van Seijen, Mette S. van Ramshorst, Esther H. Lips, Jelle Wesseling, Tessa G Steenbruggen, Liselore Maria Janssen, Erik van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Publikováno v:
Clinical cancer research, 25(16), 4985-4992. American Association for Cancer Research Inc.
Purpose: In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of patients wit